The headline of Actinium's fiscal second quarter is a 100% revenue print against no commercial product. Total revenue of $35.0 million is entirely "other revenue" - the four-year-deferred $35.0 million upfront payment from Immedica, which licensed Iomab-B for the EUMENA region in April 2022, recognized now because Immedica has notified Actinium it will not pursue European regulatory approval and the partner's window to claw the money back has expired. Net income is $27.9 million, or $0.89 per diluted share, against a year-ago loss of $6.9 million ($0.22). On a single line of accounting, the quarter is a $34.8 million positive swing. Strip that line out and the operating business ran close to break-even on a $7.4 million total opex base. The market priced the quarter in two pieces: a roughly 22% intraday bounce the day the Q2 report landed, and a stock that is still trading near its 52-week low.
The reason the bounce was modest is that the accounting is genuinely one-off and the operating business is not yet self-funding. Six-month operating cash outflow was $11.0 million against $36.8 million of cash on the balance sheet, and the $35.0 million revenue recognition is non-cash - the $35 million was already received in May 2022 and sat on the long-term deferred-revenue line for four years. Investors were right to be measured. Two facts about this quarter, however, are durable in a way the $35 million print is not. First, the NYSE American listing deficiency that the company's most recent quarterly report disclosed has, in the same report, technically resolved - stockholders' equity of $30.3 million at 6/30/2026 is well above the $4.0 million Section 1003(a)(ii) threshold, and management said it expects to remain in technical compliance thereafter. The ".BC" suffix on the ticker, the compliance plan submitted June 18, and the November 27, 2027 plan-period deadline all remain in force until NYSE American formally accepts the plan, but the numbers no longer trip the rule. Second, the underlying opex discipline is real: H1 2026 R&D fell 24% to $9.6 million and G&A fell 67% to $3.8 million, the latter pulled down by a 2025 option-cancellation non-cash charge that did not recur, but also by a 14% workforce reduction and a strategic-pipeline prioritization. Operating discipline is not the same as a turn to profitability - but it is the foundation one is built on.
The pipeline itself did not change this quarter, and that is the part of the story that matters most for the next twelve months. ATNM-400, the lead solid-tumor program, is still the asset the company is rebuilding around - first-in-class Ac-225 antibody radioconjugate, pan-tumor potential across mCRPC, NSCLC, and breast, IND-track targeting first-in-human in the fourth quarter of 2026 and into 2027. The Iomab-B SIERRA follow-on Phase 2/3 in elderly relapsed/refractory AML - for which Actinium has FDA alignment - is sitting on the back of a SIERRA trial that completed but did not meet its primary endpoint in 2024, with composition-of-matter patents extending into 2038. Actimab-A, the CD33 program, is in the same Phase 2/3-ready bucket. The H1 R&D line of $9.6 million is the spend behind that preclinical work. The questions the third quarter will answer are not pipeline questions - they are balance-sheet questions, listing-rule questions, and dilution questions. The numbers below decide the rest.